[Abionic SA]
Out Of The Blocks, May 2012
Brief profiles of these recently formed companies: Abionic, Alcresta, Avenir Medical, Avion Pharmaceuticals, Ground Fluor Pharmaceuticals and Milo Biotechnology.
More from Archive
More from In Vivo
• By
João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.
• By
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
• By
Kevin Parker leads Cartography Biosciences in developing precision therapies for underserved cancer types, targeting proteins exclusive to tumor cells.